Document:

Exhibit

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

                                                                                                                                         Exhibit 10.41

Amendment to Non-Exclusive Distribution Agreement

This Amendment to the Non-Exclusive Distribution Agreement (“Amendment”) is made as of April 30, 2016, by and between DexCom, Inc., a Delaware corporation, with a principal place of business at 6340 Sequence Drive, San Diego, California 92121 ("DexCom") and RGH Enterprises, Inc., an Ohio corporation with offices at 1810 Summit Commerce Park, Twinsburg, Ohio 44087 (the “Distributor”).  Each of DexCom and the Distributor are sometimes referred to individually herein as a "Party" and collectively as the "Parties."  Capitalized terms not defined herein shall have the meanings set forth in the Agreement (as defined in the first recital below).

RECITALS

WHEREAS, DexCom and Distributor previously entered into a Non-Exclusive Distribution Agreement, effective April 30, 2008, as has been and may be amended from time to time, (collectively, the “Agreement”).

WHEREAS, DexCom and Distributor wish to amend the Agreement as set forth herein in accordance with Section 6.1 and 16.9 of the Agreement.

NOW, THEREFORE, BE IT RESOLVED, that for good and valuable consideration, the sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:

AGREEMENT

A.  Rebates

		
	1.
	Sales Reports. Each week during the Term, Distributor agrees to provide DexCom with a weekly report identifying the volume of continuous glucose monitoring products that are listed on Schedule 1 to the Agreement (the “Products”) purchased by Distributor from DexCom during the preceding 45 days.

		
	2.
	Rebate. DexCom shall pay Distributor a monthly rebate equal to [***]% of Distributor’s aggregate dollar value of purchases of Products from DexCom during the preceding month, net of any rebates or returns (the “Rebate”). The Rebate shall be payable by DexCom to Distributor in the form of a credit memo within thirty (30) days following the end of each month, commencing on the Effective Date. The credit memo shall fully and accurately describe the amount of the Rebate earned during the previous month. Should Distributor not receive the credit memo within this time period, Distributor may deduct the amount of the Rebate from any subsequent payment owed by Distributor to DexCom. 

		
	3.
	Term and Termination. The earning and calculation of the Rebate payable under this Amendment shall commence on July 1, 2016 (the “Effective Date”) and shall continue each month thereafter until the [***]. The Agreement, except as amended by this Amendment, shall remain in full force and effect. The obligation to pay Rebates accrued during the Term shall survive any termination of the Agreement. 

1

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

		
	4.
	Compliance with Law. The prices provided for Products under the Agreement reflect discounts, and the Rebates constitute additional discounts.  Each of the Parties shall comply with applicable provisions of 42 C.F.R. § 1001.952(h) (the Anti-Kickback Statute discount safe harbor regulations).  Distributor shall fully and accurately reflect such discounts in submissions to federal healthcare programs (if any) and, upon request by the Secretary of the U.S. Department of Health and Human Services or a state agency, shall make available information provided to it by DexCom concerning the discounts.  Each of the Parties will act in compliance with all federal and state laws in the performance of their respective obligations under the Agreement as amended by this Amendment. 

B.  Sales Tracing Data
		
	1.
	Schedule 3 to the Agreement, setting forth the Sales Tracing Report Format, is amended and restated in its entirety to be as set forth in Schedule 3 to this Amendment.

C.  Stocking Requirement
		
	1.
	Distributor shall stock not more than one (1) month of Product inventory at all times with the exact amount of inventory so stocked to vary based on demand fluctuations.  Distributor agrees not to sell any sensors where the shelf-life on the sensors is less than the time of reasonable consumption by its Customers, and in no instance to ship sensors with a shelf-life of less than two (2) months.

		
	2.
	Distributor shall use good faith efforts to provide, within five (5) business days of the end of each calendar month, a report detailing Distributor’s month-end inventory balance of Products (which report shall be subject to the audit right in Section 6.1.9 of the Agreement).

[Signature Page Follows]

2

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

The Parties hereto have caused this Amendment to be duly executed on their behalf by the first date written above. 

	
					
	DEXCOM, INC.

	 
	RGH ENTERPRISES, INC. D/B/A CARDINAL HEALTH AT HOME

	 
	/s/ Jess Roper               
	 
	 
	/s/ Steve Briggs            

	Print Name:
	Jess Roper         
	 
	Print Name:
	Steve Briggs                     

	Title:
	CFO               
	 
	Title:
	VP/ GM Category Management

3

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED INFORMATION.

SCHEDULE 3
Sales Tracing Report Format
Core Data Elements – Edgepark
	
		
	Reporting Frequency
	Daily

	Reporting Period
	Rolling 45 Days

	File Format
	Pipe Delimited CSV

	Delivery Method
	Dexcom Provided sFTP

	
	
	Not required in tracing files, but provide to Dexcom to keep on file:
•Distributor Location NPI 

	
					
	 	Type
	Field Name
	Sample Value
	Comments

	 
	 	[***]
	[***]
	[***]
	[***]

	 	[***]
	[***]
	[***]

	 	[***]
	[***]
	[***]

	 	[***]
	[***]
	[***]
	[***]

	 	[***]
	[***]
	[***]

	 	[***]
	[***]
	[***]

	 	[***]
	[***]
	[***]

	 	[***]
	[***]
	[***]

	 	[***]
	[***]
	[***]

	 	[***]
	[***]
	[***]

	 	[***]
	[***]
	[***]

	 	[***]
	[***]
	[***]

	 	[***]
	[***]
	[***]

	 	[***]
	[***]
	[***]

	 	[***]
	[***]
	[***]

	 	[***]
	[***]
	[***]
	[***]

	 	[***]
	[***]
	[***]

	 	[***]
	[***]
	[***]

	 	[***]
	[***]
	[***]

	 	[***]
	[***]
	[***]

	 	[***]
	[***]
	[***]

	 	[***]
	[***]
	[***]

	 	[***]
	[***]
	[***]

	 	[***]
	[***]
	[***]
	[***]

	 	[***]
	[***]
	[***]

	 	[***]
	[***]
	[***]
	[***]

	 	[***]
	[***]
	[***]

	 	[***]
	[***] [***]
	[***]

	 	[***]
	[***]
	[***]

	 	[***]
	[***]

	[***]

1 [***] 
2 [***]Exhibit

Exhibit 10.3
AMENDMENT NO. 4 
TO THE 
CAESARS ENTERTAINMENT CORPORATION 
2012 PERFORMANCE INCENTIVE PLAN
This Amendment No. 4 (“Amendment”) to the Caesars Entertainment Corporation 2012 Performance Incentive Plan (the “Plan”), is adopted by Caesars Entertainment Corporation, a Delaware corporation (the “Company”). Capitalized terms used in this Amendment and not otherwise defined shall have the same meanings assigned to them in the Plan.
RECITALS
A.    Section 8.6 of the Plan provides that the Board of Directors of the Company (the “Board”) may amend or modify the Plan from time to time; provided such amendments or modifications do not require the approval of the stockholders pursuant to applicable law or regulations.
B.     The Board believes it to be in the best interests of the Company and its stockholders to amend and restate Section 8.5 of the Plan, and the Board has determined that, due to the nature of the changes proposed, stockholder approval is not required or advisable with respect to this Amendment.
AMENDMENT
1.    Section 8.5 of the Plan is hereby amended and restated in its entirety to read as follows:
		
	8.5
	Tax Withholding. Upon any exercise, vesting, or payment of any award, or upon the disposition of shares of Common Stock acquired pursuant to the exercise of an ISO prior to satisfaction of the holding period requirements of Section 422 of the Code, or upon any other tax withholding event with respect to any award, the Corporation or one of its Subsidiaries shall have the right at its option to:

		
	(a)
	require the participant (or the participant’s personal representative or beneficiary, as the case may be) to pay or provide for payment of at least the minimum amount of any taxes which the Corporation or one of its Subsidiaries may be required to withhold with respect to such award event or payment; or

		
	(b)
	deduct from any amount otherwise payable in cash (whether related to the award or otherwise) to the participant (or the participant’s personal representative or beneficiary, as the case may be) the amount of any taxes which the Corporation or one of its Subsidiaries may be required to withhold with respect to such award event or payment.

In any case where a tax is required to be withheld in connection with the delivery of shares of Common Stock under this Plan, the Administrator may in its sole discretion (subject to Section 8.1) require or grant (either at the time of the award or thereafter) to the participant the right to elect, pursuant to such rules and subject 

to such conditions as the Administrator may establish, that the Corporation reduce the number of shares to be delivered by (or otherwise reacquire) the appropriate number of shares, valued in a consistent manner at their fair market value or at the sales price in accordance with authorized procedures for cashless exercises, necessary to satisfy the applicable withholding obligation on exercise, vesting or payment. In no event shall the shares withheld exceed the whole number of shares allowed for tax withholding under applicable law.
		
	2.
	Except as otherwise expressly set forth in this Amendment, all other Articles, Sections, terms and conditions of the Plan remain unchanged and in full force and effect.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00260-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00260-of-00352.parquet"}]]